The N-glycosylation of Equine Tetherin Affects Antiviral Activity by Regulating Its Subcellular Localization
Overview
Authors
Affiliations
Tetherin is an interferon-inducible type II transmembrane glycoprotein which inhibits the release of viruses, including retroviruses, through a "physical tethering" model. However, the role that the glycosylation of tetherin plays in its antiviral activity remains controversial. In this study, we found that mutation of N-glycosylation sites resulted in an attenuation of the antiviral activity of equine tetherin (eqTHN), as well as a reduction in the expression of eqTHN at the plasma membrane (PM). In addition, eqTHN N-glycosylation mutants colocalize obviously with ER, CD63, LAMP1 and endosomes, while WT eqTHN do not. Furthermore, we also found that N-glycosylation impacts the transport of eqTHN in the cell not by affecting the endocytosis, but rather by influencing the anterograde trafficking of the protein. These results suggest that the N-glycosylation of eqTHN is important for the antiviral activity of the protein through regulating its normal subcellular localization. This finding will enhance our understanding of the function of this important restriction factor.
Equine Infectious Anemia Virus Cellular Partners Along the Viral Cycle.
Schimmich C, Vabret A, Zientara S, Valle-Casuso J Viruses. 2025; 17(1).
PMID: 39861793 PMC: 11769393. DOI: 10.3390/v17010005.
Tanwattana N, Wanasen N, Jantraphakorn Y, Srisutthisamphan K, Chailungkarn T, Boonrungsiman S PLoS One. 2023; 18(11):e0292833.
PMID: 37922253 PMC: 10624315. DOI: 10.1371/journal.pone.0292833.
Host cell restriction factors of equine infectious anemia virus.
Wang X, Zhang X, Ma W, Li J, Wang X Virol Sin. 2023; 38(4):485-496.
PMID: 37419416 PMC: 10436108. DOI: 10.1016/j.virs.2023.07.001.
A Novel, Fully Spliced, Accessory Gene in Equine Lentivirus with Distinct Rev-Responsive Element.
Zhang X, Li J, Zhang M, Bai B, Ma W, Lin Y J Virol. 2022; 96(18):e0098622.
PMID: 36069548 PMC: 9517694. DOI: 10.1128/jvi.00986-22.
Ao D, Liu X, Jiang S, Xu Y, Zheng W, Chen N Vaccines (Basel). 2022; 10(1).
PMID: 35062674 PMC: 8778924. DOI: 10.3390/vaccines10010014.